Sumanta K. Pal, MD, on Advanced RCC: Tivozanib to Treat Disease Progression After Axitinib
2021 Genitourinary Cancers Symposium
Sumanta K. Pal, MD, of City of Hope, discusses findings of the TIVO-3 study, which showed that the tyrosine kinase inhibitor tivozanib improved progression-free survival vs sorafenib in patients whose advanced renal cell carcinoma progressed after multiple lines of therapy (Abstract 278).
The ASCO Post Staff
Felix Y. Feng, MD, of the University of California, San Francisco, discusses study findings showing that molecular determinants may help clinicians select patients with nonmetastatic castration-resistant prostate cancer who may derive the most benefit from apalutamide and other androgen-signaling inhibitors (Abstract 8).
The ASCO Post Staff
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discusses phase III findings from the IPATential150 trial, which showed the effectiveness of ipatasertib plus abiraterone as first-line treatment in patients with metastatic castration-resistant prostate cancer vs placebo plus abiraterone. Analyses of biomarkers linked to the PI3K/AKT pathway, a subtype with a poor prognosis, further support this therapeutic option (Abstract 13).
The ASCO Post Staff
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discuses a preliminary phase II analysis of the HIF-2a inhibitor belzutifan in combination with cabozantinib, which showed antitumor activity in previously treated patients with metastatic clear cell renal cell carcinoma (Abstract 272).
The ASCO Post Staff
Daniel M. Geynisman, MD, of Fox Chase Cancer Center, discusses phase II results from the RETAIN BLADDER study, which sequenced bladder tumor samples while treating patients with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. The goal was to increase metastasis-free survival and also preserve the bladder and quality of life (Abstract 397).
The ASCO Post Staff
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses phase III results from the KEYNOTE-426 study—specifically, an exploratory subgroup analysis of patients with advanced renal cell carcinoma who were randomly assigned to receive pembrolizumab plus axitinib and completed 2 years of treatment (Abstract 327).